Small molecule signal transduction inhibitors for the treatment of solid tumors (Q36895413)

16 August 2017

1 reference

title

Small molecule signal transduction inhibitors for the treatment of solid tumors (English)

1 reference

16 August 2017

Alexandra Leary

1

1 reference

PubMed ID

17661211

16 August 2017

Stephen R D Johnston

series ordinal

2

1 reference

16 August 2017

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

25

1 reference

16 August 2017

5

1 reference

16 August 2017

347-365

1 reference

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Development of farnesyl transferase inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase II study of E7070 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Drugging cell cycle kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

The state of the STATs: recent developments in the study of signal transduction to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701259694

10.1080/07357900701259694

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17661211